Comparative Performance Analysis of Idylla and Archer in the Detection of Gene Fusions in Spitzoid Melanocytic Tumors
Modern Pathology · 2024
DOI: 10.1016/j.modpat.2024.100538 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Modern Pathology, 2024. Verfasst von Chiel F Ebbelaar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Division of Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands; Dep…. Hauptthemen laut MEDLINE: Skin Neoplasms, Nevus, Epithelioid and Spindle Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Melanocytic neoplasms with spitzoid histomorphology are often difficult to classify without identifying genetic drivers such as kinase fusions. Traditional diagnostic methods, such as immunohistochemistry, can yield inconclusive results, and advanced techniques such as the Archer fusion assay are often inaccessible and costly. The Idylla GeneFusion Assay might offer a rapid and cost-effective alternative. This study compared Idylla and Archer in identifying ALK, pan-NTRK, RET, and ROS1 gene fusions. Of the 147 samples where next-generation sequencing did not detect genetic drivers, 89 (60.5%) meeting the tissue requirements were further analyzed using Idylla (Cohort A). Idylla demonstrated a sensitivity of 75% and a specificity of 100% in detecting these fusions. Additionally, among 27 randomly selected cases (Cohort B) that failed to meet the inclusion criteria, Idylla maintained the same levels of sensitivity and specificity. Our findings also show that Idylla can be effectively conducted with isolated RNA, broadening its applicability beyond tissue samples. Although the Idylla assay may not replace more comprehensive molecular assays such as Archer, it could serve as a valuable initial screening tool in diagnosing spitzoid melanocytic tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Division of Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Dermatology, Leiden University Medical Center, Leiden, The…
- Department of Pathology, Division of Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Zitieren
APA
Ebbelaar, C. F., van Dijk, M., Breimer, G. E., Meijers, R. W. J., Klein, L. B. C., Petronilia, M. M., de Leng, W. W. J., Blokx, W. A. M., Jansen, A. M. L., & MOLecular Evaluation of Melanocytic Ambiguous Tumors (MOLEMAT) investigators (2024). Comparative Performance Analysis of Idylla and Archer in the Detection of Gene Fusions in Spitzoid Melanocytic Tumors. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100538
Vancouver
Ebbelaar CF, van Dijk M, Breimer GE, Meijers RWJ, Klein LBC, Petronilia MM, et al. Comparative Performance Analysis of Idylla and Archer in the Detection of Gene Fusions in Spitzoid Melanocytic Tumors. Modern Pathology. 2024. doi:10.1016/j.modpat.2024.100538
BibTeX
@article{Ebbelaar2024,
author = {Ebbelaar, Chiel F and van Dijk, Marijke and Breimer, Gerben E and Meijers, Ruud W J and Klein, Laura B C and Petronilia, Maryleen M and de Leng, Wendy W J and Blokx, Willeke A M and Jansen, Anne M L and MOLecular Evaluation of Melanocytic Ambiguous Tumors (MOLEMAT) investigators, MOLecular Evaluation of Melanocytic Ambiguous Tumors (MOLEMAT) investigators},
title = {Comparative Performance Analysis of Idylla and Archer in the Detection of Gene Fusions in Spitzoid Melanocytic Tumors},
journal = {Modern Pathology},
year = {2024},
doi = {10.1016/j.modpat.2024.100538}
}
EUVIMED